9 results about "T cell differentiation" patented technology

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The current disclosure provides methods and compositions that provide for the insertion of transgenes in stem or progenitor cells without the deleterious effects to T cell differentiation by in vitro T cell differentiation methods. To accomplish this, the inventors have discovered that expression of the transgenes under the control of promoter regions, such as CD8a or CD8b, allows for the coordinated expression pattern that provides for both: 1) high expression of the transgene in mature T cells and 2) a coordinated level of expression of the transgene throughout the in vitro differentiation method that allows for the production of a population of mature T cells.

The application discloses application of targeting ENPP1 in treatment of systemic lupus erythematosus, and the systemic lupus erythematosus has CD4 + T cell abnormal differentiation and induction of CD4 + T cell abnormal differentiation mtDNA, new recognizable molecule ENPP1 exists in mtDNA, and CD4 + T cell differentiation is induced by ENPP1 as a target point for treating systemic lupus erythematosus. The application provides the application of targeting ENPP1 in treatment of systemic lupus erythematosus, and the application explores the action mechanism of mtDNA on CD4 + T cell differentiation, focuses on a new recognizable molecule ENPP1 of mtDNA, and CD4 + T cell differentiation is induced by ENPP1 as a target point for treating systemic lupus erythematosus, and a new strategy for treating systemic lupus erythematosus is excavated.

The technology described herein is directed to improved methods of T cell differentiation. Also described herein are immune cells differentiated using such methods and compositions comprising such immune cells. In some embodiments, the immune cells can be genetically modified. In some embodiments, the immune cells or compositions comprising said immune cells can be administered to a patient as a cellular replacement therapy to treat a condition.

The invention is applicable to the technical field of biomedicine and immunological detection, and provides a reagent composition, a kit and a method for risk prediction of senile deafness, the reagent composition contains three types of fluorescence labeled antibody combinations: T cell surface marker antibodies CD3, CD4 and CD8; a T cell differentiation and activation marker antibody CCR7, CD45RA, HLA-DR and CD38; and natural killer cell functional marker antibodies CD56 and NKP30. The expression level of related lymphocyte subpopulations and functional markers thereof in peripheral blood is detected through flow cytometry, the'immune-auditory axis' association of immune aging and auditory degeneration is revealed, and a multi-parameter prediction model integrating age and immune indexes is constructed. The model can realize early recognition, risk stratification and accurate evaluation of senile deafness of middle-aged and elderly people. The method has the advantages of high prediction accuracy, early warning, non-invasiveness, simplicity and convenience in operation and the like, and has a wide application prospect.

The invention relates to the technical field of in-vitro cell model construction, and particularly discloses an in-vitro airway allergen presentation model and a construction method and application thereof. A double-catheter structure is prepared by adopting a 3D printing method, the inner tube is inoculated with human pulmonary epithelial cells, the bottom end of the inner tube is closed to reconstruct an airway mucosa physical barrier in a bionic manner, and the outer tube loads, induces and activates an innate immune cell subset to simulate an airway mucosa immune surveillance microenvironment; the double catheters are placed in a culture medium system containing peripheral blood mononuclear cells or / and CD4 + T cells, a culture medium containing to-be-detected allergens is added into the inner tube for multi-cell co-culture, and a highly-bionic in-vitro airway allergen presentation model is constructed. Multi-index detection of immune cell chemotaxis, T cell infiltration, cytokine secretion and T cell differentiation is achieved through immunofluorescence, ELISA and flow cytometry at the same time, diversified requirements of mechanism research and drug screening are met, and detection dimensions are comprehensive.

This invention relates to an alanine-modified fullerene, its preparation method, pharmaceutical composition, and applications, belonging to the field of biomedical technology. It addresses the problems in existing treatments for type 1 diabetes, namely, the difficulty in safely and effectively protecting pancreatic β-cells while blocking autoimmune attacks, and the lack of pancreatic tissue-specific targeting ability in existing fullerene derivatives. The alanine-modified fullerene has the general formula shown in Formula I: C 70 - (Ala) n Equation I, where C 70 For fullerenes, Ala is an alanine group, and n is the number of atoms linked to each fullerene C. 70 The average number of alanine groups is taken as an integer from 1 to 20. The alanine-modified fullerene of the present invention has the targeting ability to specifically accumulate in pancreatic islet tissue in vivo, as well as the immunomodulatory function of inhibiting dendritic cell antigen presentation and regulating T cell differentiation, which can achieve efficient intervention on the core pathological links of type 1 diabetes.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and discloses a TCM composition for treating ulcerative colitis, its preparation method, and its uses. The TCM composition comprises the following raw materials in parts by weight: 2-10 parts of charred Typhae Pollen, 3-7 parts of charred Scutellariae Radix, 4-6 parts of charred Angelicae Sinensis Radix, 3-8 parts of charred Sophorae Fructus, 6-10 parts of Prunus Mume, 2-10 parts of prepared Zingiberis Rhizoma, 5-7 parts of prepared Aconitum Carmichaelii Radix, 3-7 parts of Coptise Rhizoma, and 1-8 parts of Indigo Naturalis Radix. Among these, Prunus Mume is the principal ingredient, with prepared Zingiberis Rhizoma and prepared Aconitum Carmichaelii Radix as assistant ingredients, and charred Angelicae Sinensis Radix, charred Sophorae Fructus, charred Typhae Pollen, charred Scutellariae Radix, Coptise Rhizoma, and Indigo Naturalis as adjuvants. The synergistic effect among the various TCM components gives the TCM composition of this invention the effects of soothing the liver and strengthening the spleen, astringing the intestines and stopping bleeding. It is mainly used to treat moderate to severe ulcerative colitis. Experiments have demonstrated that the traditional Chinese medicine composition of this invention can inhibit intestinal inflammatory response in mice with ulcerative colitis; improve pathological histological damage and promote intestinal mucosal repair; regulate macrophage polarization and restore the balance of M1 / M2 macrophages; regulate CD4+ T cell differentiation and reshape Th17 / Treg cell immune homeostasis.

It was discovered that ICIs elevated extracellular NAD levels and conferred cancer cells resistance to ICIs. It was also discovered that NAMPT was induced by IFN-y and ICIs resulting in an increase of extracellular NAD level, which could be reduced by NAMPT knockdown. NAMPT deficiency in HCC sensitized tumors to anti-PD-1 treatment. It was further discovered that extracellular NAD promoted T cell apoptosis, exhaustion, and T cell differentiation to regulatory T cells. The blockade of P2X7R reversed the immunosuppressive effect of NAD and worked effectively in combination with immunotherapies, indicating that it can be a combination therapeutic approach for ICI-resistant tumors. It was shown that serum NAD level can be a predictive biomarker for ICI responses in HCC. Overall, extracellular NAD was shown to act as an immunosuppressive metabolite that could serve as a biomarker for ICI responses and the P2X7R can be a therapeutic target to improve ICI efficacy.